Moberg Pharma: Delivers its fourth license agreement for MOB-015

Research Note

2019-10-21

09:04

Today's announced agreement with DongKoo provides a commercial presence in the relatively large (~USD 40m) and fast-growing South Korean topical nail fungus market. DongKoo seems to be a perfect distribution partner for MOB-015, with a strong presence at the dermatology clinics.

KP

Klas Palin

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.